Frequently Asked Questions

Response was rapid in this pilot sample. All 10 participants met HAMD response criteria by H72, 60% achieved response by H24, 80% achieved remission by H48, and 9 of 10 had remitted by H72. Among the 9 who remitted, the mean time to remission was 39.1 hours (±16.2) from the start of the infusion, and remission was still present at D30 in all 9 who had remitted during treatment.

Yes. The authors noted that clinical response was often observed before the highest brexanolone dose began at Hour 24. In this study, 60% of participants had already met response criteria by H24, even though the FDA-approved infusion reaches 90 µg/kg/hour only from Hours 24 to 52.

No. The study did not find a single leading symptom that consistently preceded response across participants. Anxiety appeared to lead in some women, depressed mood improved first in others, and in some cases affective symptoms improved only after sleep improved, so the symptom trajectory was heterogeneous rather than uniform.

Anxiety improved substantially during and after the infusion. STAI-State scores decreased by a mean of 26.9 points by H72 (P<.001) and 28.8 points by D30 (P<.001), while STAI-Trait scores decreased by 27.3 points by H72 (P<.001) and 33.1 points by D30 (P<.001). The HAMD anxiety subscale also showed progressive improvement, as part of the 88% to 93% improvement range seen across HAMD subscales from H0 to H72.

Not always. The authors found that subjective ratings of mood satisfaction and desire to maintain one's current mood often diverged from HAMD and STAI-S changes, and in 8 of 10 participants the timing of maximal change in these subjective measures differed from maximal changes in standard symptom scales. In several participants, subjective changes were the first sign of a state shift, while in others they occurred only after clinical remission.

Yes, both improved by H72. SHAPS scores for anhedonia fell 89%, from 6.2 (±3.7) at baseline to 0.7 (±1.1) at H72, with a mean difference of -5.5 (P<.001), and the mean score at H72 and D30 was below the threshold for clinically significant anhedonia. RRS scores for rumination decreased 29%, from 28.4 (±12.5) to 20.3 (±8.3), with a mean difference of -8.1 (P=.008).

Yes. Self-reported maternal functioning on the BIMF increased 56% from baseline to H72, rising from 58.5 (±9.2) to 91.3 (±16.8), with a mean difference of 32.8 points (P<.001). Improvement continued at D30, with a mean difference of 42.7 points from baseline (P<.001), and gains were seen in both the Competency and Maternal Needs subscales.

Adverse events were mild and expected in this sample. Reported events included warm flushing in 4 participants, transient dizziness in 4, headache in 3, and venipuncture-site discomfort or bruising in 3.

This was a single-arm, open-label, descriptive pilot study of 10 women with moderate-to-severe postpartum depression. Participants were 18 to 45 years old, within 8 months postpartum, met DSM-5 criteria for major depressive disorder with peripartum onset, and had baseline HAMD scores of 21 or higher. They received the FDA-approved 60-hour intravenous brexanolone regimen and completed symptom assessments at 13 standardized timepoints from baseline through 30-day follow-up.

The findings should be interpreted cautiously because the study was small (N=10), single-arm, open-label, and conducted in an inpatient setting with a homogeneous sample of Caucasian, non-Hispanic, married women. Participants also continued concurrent psychotropic medications, and there was no control group, so the study cannot support causal or mechanistic conclusions about brexanolone's independent contribution to symptom change. The authors describe temporal features of recovery rather than treatment efficacy or definitive symptom sequencing.